Efficacy and safety of pregabalin for treating painful diabetic peripheral neuropathy: a meta‐analysis
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background: Pregabalin is considered to be an effective treatment for painful diabetic peripheral neuropathy (DPN), but controversy exists about its efficacy and safety. We performed a meta‐analysis to systematically assess the efficacy and safety of pregabalin for managing pain associated with DPN. Methods: M edline, EMBASE, and the C ochrane C entral R egister were searched in J uly 2014 for randomized, double‐blind, placebo‐controlled trials published in E nglish on the use of pregabalin to treat DPN‐associated pain. Principal outcomes were mean pain score after pregabalin treatment and the proportions of patients showing a pain reduction of at least 50%. Results: Nine trials involving a total of 2056 participants were identified. Pooled analysis showed that pregabalin was significantly superior to placebo for improving mean pain scores [mean difference (MD) = −0.79, P < 0.001]. Pregabalin reduced pain below baseline by at least 50% in a significantly greater proportion of patients than placebo did [relative risk = 1.54, P < 0.001]. Patients were more likely to self‐report their status as ‘improved’ after taking pregabalin than placebo (relative risk = 1.38, P < 0.001). Pregabalin also improved sleep quality more than placebo (MD = −0.88, P < 0.001). On the other hand, patients receiving pregabalin were more likely to experience mild side effects than were patients receiving placebo. Conclusions: Our meta‐analysis indicates that pregabalin is more effective than placebo for managing DPN‐associated pain and other symptoms that reduce quality of life. The drug is also reasonably well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Depression and Pain Comorbidity: A Literature Review
Bair, M. J., Robinson, R. L., Katon, W., & Kroenke, K. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.20.2433 · Cited by 3,463
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision
Attal, N., Cruccu, G., Baron, R., Haanpää, M., Hansson, P., Jensen, T. S., & Nurmikko, T. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.02999.x · Cited by 1,873
Boulton, A. J. M., Malik, R. A., Arezzo, J. C., & Sosenko, J. M. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1458 · Cited by 913
Cited by
Must we reduce pain intensity to treat chronic pain?
Sullivan, M. D., & Ballantyne, J. C. (2016) · Pain · doi:10.1097/j.pain.0000000000000336 · Cited by 164
Onakpoya, I. J., Thomas, E. T., Lee, J. J., Goldacre, B., & Heneghan, C. J. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-023600 · Cited by 132
Treating pain in diabetic neuropathy: current and developmental drugs
Alam, U., Sloan, G., & Tesfaye, S. (2020) · Drugs · doi:10.1007/s40265-020-01259-2 · Cited by 104
Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome
Saito, Y. A., Almazar, A. E., Tilkes, K. E., Choung, R. S., Van Norstrand, M. D., Schleck, C. D., Zinsmeister, A. R., & Talley, N. J. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15077 · Cited by 79
“Pregabalin has also been used to treat generalised anxiety disorder, and there is literature showing that it may help with other pain conditions such as post‐operative pain and chronic pancreatitis.(9,10) Data on pregabalin's effects on visceral pain and IBS are limited but suggest the drug does reduce gut visceral hy…”
Background
Metadata
- Authors
- ZHANG, S. ‐., WU, Z., ZHANG, L. ‐., ZHANG, Z., CHEN, R. ‐., HUANG, Y. ‐., & CHEN, H.
- Venue
- Acta Anaesthesiologica Scandinavica
- Publisher
- Wiley
- Published
- 2014-10-19
- Volume
- 59
- Issue
- 2
- Pages
- 147-159
- ISSN
- 0001-5172 (ISSN-L)
- 1399-6576
- OpenAlex
- W1665446506
- Cited by
- 39
- References
- 3
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of pregabalin for treating painful diabetic peripheral neuropathy: a meta‐analysis. https://app.cochat.ai/papers/10.1111/aas.12420
- The paper
- ZHANG, S. ‐., WU, Z., ZHANG, L. ‐., ZHANG, Z., CHEN, R. ‐., HUANG, Y. ‐., & CHEN, H. (2015). Efficacy and safety of pregabalin for treating painful diabetic peripheral neuropathy: a meta‐analysis. Acta Anaesthesiologica Scandinavica. https://doi.org/10.1111/aas.12420
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.